vs
Side-by-side financial comparison of LivaNova PLC (LIVN) and Walker & Dunlop, Inc. (WD). Click either name above to swap in a different company.
LivaNova PLC is the larger business by last-quarter revenue ($360.9M vs $340.0M, roughly 1.1× Walker & Dunlop, Inc.). LivaNova PLC runs the higher net margin — 8.6% vs -12.9%, a 21.5% gap on every dollar of revenue. On growth, LivaNova PLC posted the faster year-over-year revenue change (12.1% vs -0.4%). LivaNova PLC produced more free cash flow last quarter ($50.2M vs $-680.1M). Over the past eight quarters, Walker & Dunlop, Inc.'s revenue compounded faster (22.1% CAGR vs 10.6%).
LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
Walker & Dunlop, Inc. is one of the largest commercial real estate finance and advisory services firms in the United States and internationally.
LIVN vs WD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $360.9M | $340.0M |
| Net Profit | $30.9M | $-13.9M |
| Gross Margin | 65.2% | — |
| Operating Margin | 11.8% | -17.2% |
| Net Margin | 8.6% | -12.9% |
| Revenue YoY | 12.1% | -0.4% |
| Net Profit YoY | -44.7% | -131.0% |
| EPS (diluted) | $0.57 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $360.9M | $340.0M | ||
| Q3 25 | $357.8M | $337.7M | ||
| Q2 25 | $352.5M | $319.2M | ||
| Q1 25 | $316.9M | $237.4M | ||
| Q4 24 | $321.8M | $341.5M | ||
| Q3 24 | $318.1M | $292.3M | ||
| Q2 24 | $318.6M | $270.7M | ||
| Q1 24 | $294.9M | $228.1M |
| Q4 25 | $30.9M | $-13.9M | ||
| Q3 25 | $26.8M | $33.5M | ||
| Q2 25 | $27.2M | $34.0M | ||
| Q1 25 | $-327.3M | $2.8M | ||
| Q4 24 | $55.9M | $44.8M | ||
| Q3 24 | $33.0M | $28.8M | ||
| Q2 24 | $16.3M | $22.7M | ||
| Q1 24 | $-41.9M | $11.9M |
| Q4 25 | 65.2% | — | ||
| Q3 25 | 68.4% | — | ||
| Q2 25 | 67.8% | — | ||
| Q1 25 | 69.7% | — | ||
| Q4 24 | 68.2% | — | ||
| Q3 24 | 70.8% | — | ||
| Q2 24 | 68.7% | — | ||
| Q1 24 | 70.3% | — |
| Q4 25 | 11.8% | -17.2% | ||
| Q3 25 | 15.1% | 13.6% | ||
| Q2 25 | 15.4% | 14.5% | ||
| Q1 25 | 15.3% | 2.2% | ||
| Q4 24 | 11.5% | 15.3% | ||
| Q3 24 | 11.2% | 12.8% | ||
| Q2 24 | 12.6% | 10.4% | ||
| Q1 24 | 5.5% | 6.0% |
| Q4 25 | 8.6% | -12.9% | ||
| Q3 25 | 7.5% | 9.9% | ||
| Q2 25 | 7.7% | 10.6% | ||
| Q1 25 | -103.3% | 1.2% | ||
| Q4 24 | 17.4% | 13.1% | ||
| Q3 24 | 10.4% | 9.9% | ||
| Q2 24 | 5.1% | 8.4% | ||
| Q1 24 | -14.2% | 5.2% |
| Q4 25 | $0.57 | $-0.41 | ||
| Q3 25 | $0.49 | $0.98 | ||
| Q2 25 | $0.50 | $0.99 | ||
| Q1 25 | $-6.01 | $0.08 | ||
| Q4 24 | $1.04 | $1.32 | ||
| Q3 24 | $0.60 | $0.85 | ||
| Q2 24 | $0.30 | $0.67 | ||
| Q1 24 | $-0.78 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $635.6M | $299.3M |
| Total DebtLower is stronger | $376.1M | — |
| Stockholders' EquityBook value | $1.2B | $1.7B |
| Total Assets | $2.6B | $5.1B |
| Debt / EquityLower = less leverage | 0.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $635.6M | $299.3M | ||
| Q3 25 | $646.1M | $274.8M | ||
| Q2 25 | $593.6M | $233.7M | ||
| Q1 25 | $738.4M | $181.0M | ||
| Q4 24 | $428.9M | $279.3M | ||
| Q3 24 | $346.4M | $179.8M | ||
| Q2 24 | $329.2M | $208.1M | ||
| Q1 24 | $309.2M | $216.5M |
| Q4 25 | $376.1M | — | ||
| Q3 25 | $434.5M | — | ||
| Q2 25 | $430.6M | — | ||
| Q1 25 | $628.2M | — | ||
| Q4 24 | $627.0M | — | ||
| Q3 24 | $625.5M | — | ||
| Q2 24 | $624.5M | — | ||
| Q1 24 | $623.8M | — |
| Q4 25 | $1.2B | $1.7B | ||
| Q3 25 | $1.2B | $1.8B | ||
| Q2 25 | $1.1B | $1.8B | ||
| Q1 25 | $1.0B | $1.7B | ||
| Q4 24 | $1.3B | $1.7B | ||
| Q3 24 | $1.3B | $1.7B | ||
| Q2 24 | $1.2B | $1.7B | ||
| Q1 24 | $1.2B | $1.7B |
| Q4 25 | $2.6B | $5.1B | ||
| Q3 25 | $2.6B | $5.8B | ||
| Q2 25 | $2.5B | $4.7B | ||
| Q1 25 | $2.6B | $4.5B | ||
| Q4 24 | $2.5B | $4.4B | ||
| Q3 24 | $2.5B | $4.6B | ||
| Q2 24 | $2.5B | $4.2B | ||
| Q1 24 | $2.5B | $3.8B |
| Q4 25 | 0.31× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.51× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $82.4M | $-664.3M |
| Free Cash FlowOCF − Capex | $50.2M | $-680.1M |
| FCF MarginFCF / Revenue | 13.9% | -200.0% |
| Capex IntensityCapex / Revenue | 8.9% | 4.6% |
| Cash ConversionOCF / Net Profit | 2.67× | — |
| TTM Free Cash FlowTrailing 4 quarters | $173.3M | $-2.2B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.4M | $-664.3M | ||
| Q3 25 | $85.1M | $-948.1M | ||
| Q2 25 | $62.9M | $-238.5M | ||
| Q1 25 | $24.0M | $-281.1M | ||
| Q4 24 | $78.7M | $129.4M | ||
| Q3 24 | $51.0M | $-202.0M | ||
| Q2 24 | $43.4M | $-237.8M | ||
| Q1 24 | $10.0M | $38.4M |
| Q4 25 | $50.2M | $-680.1M | ||
| Q3 25 | $62.2M | $-950.4M | ||
| Q2 25 | $47.8M | $-241.0M | ||
| Q1 25 | $13.2M | $-284.7M | ||
| Q4 24 | $68.3M | $116.4M | ||
| Q3 24 | $32.8M | $-204.0M | ||
| Q2 24 | $31.2M | $-241.7M | ||
| Q1 24 | $3.6M | $35.2M |
| Q4 25 | 13.9% | -200.0% | ||
| Q3 25 | 17.4% | -281.5% | ||
| Q2 25 | 13.6% | -75.5% | ||
| Q1 25 | 4.2% | -120.0% | ||
| Q4 24 | 21.2% | 34.1% | ||
| Q3 24 | 10.3% | -69.8% | ||
| Q2 24 | 9.8% | -89.3% | ||
| Q1 24 | 1.2% | 15.4% |
| Q4 25 | 8.9% | 4.6% | ||
| Q3 25 | 6.4% | 0.7% | ||
| Q2 25 | 4.3% | 0.8% | ||
| Q1 25 | 3.4% | 1.5% | ||
| Q4 24 | 3.2% | 3.8% | ||
| Q3 24 | 5.7% | 0.7% | ||
| Q2 24 | 3.8% | 1.4% | ||
| Q1 24 | 2.2% | 1.4% |
| Q4 25 | 2.67× | — | ||
| Q3 25 | 3.18× | -28.34× | ||
| Q2 25 | 2.32× | -7.02× | ||
| Q1 25 | — | -102.07× | ||
| Q4 24 | 1.41× | 2.89× | ||
| Q3 24 | 1.55× | -7.01× | ||
| Q2 24 | 2.65× | -10.49× | ||
| Q1 24 | — | 3.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
WD
Segment breakdown not available.
